![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1314359 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of OLIG3 mRNA | CTD | PMID:22206623 | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | RGD:1314359 | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,2',5,5'-tetrachlorobiphenyl | multiple interactions | ISO | RGD:1314359 | 6480464 | [2 more ... | CTD | PMID:25510870 | 3,3',5,5'-tetrabromobisphenol A | decreases expression | ISO | RGD:1314358 | 6480464 | tetrabromobisphenol A results in decreased expression of OLIG3 mRNA | CTD | PMID:33476716 | 5-fluorouracil | decreases expression | ISO | RGD:1314358 | 6480464 | Fluorouracil results in decreased expression of OLIG3 mRNA | CTD | PMID:31711903 | abacavir | increases expression | ISO | RGD:1314358 | 6480464 | abacavir results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | aflatoxin B1 | decreases methylation | ISO | RGD:1314358 | 6480464 | Aflatoxin B1 results in decreased methylation of OLIG3 gene | CTD | PMID:27153756 | all-trans-retinoic acid | multiple interactions | ISO | RGD:1314358 | 6480464 | [Chir 99021 co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | all-trans-retinoic acid | increases expression | ISO | RGD:1314358 | 6480464 | Tretinoin results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | arsenite(3-) | increases methylation | ISO | RGD:1314358 | 6480464 | arsenite results in increased methylation of OLIG3 promoter | CTD | PMID:23974009 | benzo[a]pyrene | decreases expression | ISO | RGD:1314358 | 6480464 | Benzo(a)pyrene results in decreased expression of OLIG3 mRNA | CTD | PMID:22316170 | benzo[a]pyrene | increases expression | ISO | RGD:1314358 | 6480464 | Benzo(a)pyrene results in increased expression of OLIG3 mRNA | CTD | PMID:30453624 | benzo[a]pyrene | decreases methylation | ISO | RGD:1314358 | 6480464 | Benzo(a)pyrene results in decreased methylation of OLIG3 exon | CTD | PMID:27901495 | benzo[a]pyrene | affects methylation | ISO | RGD:1314358 | 6480464 | Benzo(a)pyrene affects the methylation of OLIG3 promoter | CTD | PMID:27901495 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | RGD:1314358 | 6480464 | Diethylhexyl Phthalate results in decreased expression of OLIG3 mRNA | CTD | PMID:31163220 | bisphenol A | decreases expression | ISO | RGD:1314358 | 6480464 | bisphenol A results in decreased expression of OLIG3 mRNA | CTD | PMID:33476716 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of OLIG3 gene | CTD | PMID:28505145 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of OLIG3 mRNA | CTD | PMID:25181051 | cadmium atom | multiple interactions | ISO | RGD:1314358 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OLIG3 mRNA | CTD | PMID:35301059 | cadmium dichloride | decreases expression | ISO | RGD:1314359 | 6480464 | Cadmium Chloride results in decreased expression of OLIG3 mRNA | CTD | PMID:18974090 | cadmium dichloride | multiple interactions | ISO | RGD:1314358 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OLIG3 mRNA | CTD | PMID:35301059 | caffeine | increases expression | ISO | RGD:1314358 | 6480464 | Caffeine results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | CHIR 99021 | multiple interactions | ISO | RGD:1314358 | 6480464 | [Chir 99021 co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | choline | multiple interactions | ISO | RGD:1314359 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of OLIG3 gene | CTD | PMID:20938992 | dabigatran | increases expression | ISO | RGD:1314358 | 6480464 | Dabigatran results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | dorsomorphin | multiple interactions | ISO | RGD:1314358 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1314358 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA | CTD | PMID:27188386 | ethanol | multiple interactions | ISO | RGD:1314358 | 6480464 | [Ethanol co-treated with Folic Acid] results in increased expression of OLIG3 mRNA | CTD | PMID:23378141 | ethanol | decreases expression | ISO | RGD:1314358 | 6480464 | Ethanol results in decreased expression of OLIG3 mRNA | CTD | PMID:28986285 | ethanol | increases expression | ISO | RGD:1314358 | 6480464 | Ethanol results in increased expression of OLIG3 mRNA | CTD | PMID:23378141 | ethylene glycol | increases expression | ISO | RGD:1314358 | 6480464 | Ethylene Glycol results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | folic acid | multiple interactions | ISO | RGD:1314359 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of OLIG3 gene | CTD | PMID:20938992 | folic acid | multiple interactions | ISO | RGD:1314358 | 6480464 | [Ethanol co-treated with Folic Acid] results in increased expression of OLIG3 mRNA | CTD | PMID:23378141 | fonofos | increases methylation | ISO | RGD:1314358 | 6480464 | Fonofos results in increased methylation of OLIG3 promoter | CTD | PMID:22847954 | glyphosate | increases methylation | EXP | | 6480464 | glyphosate results in increased methylation of OLIG3 gene | CTD | PMID:31011160 | isotretinoin | increases expression | ISO | RGD:1314358 | 6480464 | Isotretinoin results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | L-methionine | multiple interactions | ISO | RGD:1314359 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of OLIG3 gene | CTD | PMID:20938992 | lipopolysaccharide | multiple interactions | ISO | RGD:1314358 | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | nilotinib | increases expression | ISO | RGD:1314358 | 6480464 | nilotinib results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | panobinostat | multiple interactions | ISO | RGD:1314358 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA | CTD | PMID:27188386 | parathion | increases methylation | ISO | RGD:1314358 | 6480464 | Parathion results in increased methylation of OLIG3 promoter | CTD | PMID:22847954 | PCB138 | multiple interactions | ISO | RGD:1314359 | 6480464 | [2 more ... | CTD | PMID:25510870 | perfluorooctanoic acid | increases expression | ISO | RGD:1314358 | 6480464 | perfluorooctanoic acid results in increased expression of OLIG3 protein | CTD | PMID:22609092 | phenytoin | increases expression | ISO | RGD:1314358 | 6480464 | Phenytoin results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | resveratrol | multiple interactions | ISO | RGD:1314358 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of OLIG3 mRNA | CTD | PMID:23557933 | S-(1,2-dichlorovinyl)-L-cysteine | decreases expression | ISO | RGD:1314358 | 6480464 | S-(1, 2-dichlorovinyl)cysteine results in decreased expression of OLIG3 mRNA | CTD | PMID:35811015 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | RGD:1314358 | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | SB 431542 | decreases expression | ISO | RGD:1314358 | 6480464 | 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of OLIG3 mRNA | CTD | PMID:25670856 | SB 431542 | multiple interactions | ISO | RGD:1314358 | 6480464 | [Chir 99021 co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386, PMID:31711903 | silicon dioxide | increases expression | ISO | RGD:1314358 | 6480464 | Silicon Dioxide analog results in increased expression of OLIG3 mRNA | CTD | PMID:23806026 | terbufos | increases methylation | ISO | RGD:1314358 | 6480464 | terbufos results in increased methylation of OLIG3 promoter | CTD | PMID:22847954 | thalidomide | increases expression | ISO | RGD:1314358 | 6480464 | Thalidomide results in increased expression of OLIG3 mRNA | CTD | PMID:31711903 | trichostatin A | increases expression | ISO | RGD:1314358 | 6480464 | trichostatin A results in increased expression of OLIG3 mRNA | CTD | PMID:24935251 | valproic acid | affects expression | ISO | RGD:1314358 | 6480464 | Valproic Acid affects the expression of OLIG3 mRNA | CTD | PMID:25979313 | valproic acid | increases expression | ISO | RGD:1314358 | 6480464 | Valproic Acid results in increased expression of OLIG3 mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | RGD:1314358 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RGD:1314358 | 6480464 | Valproic Acid results in decreased expression of OLIG3 mRNA | CTD | PMID:34742744 | |